New study identifies immune signals that track visceral Leishmaniasis treatment success Visceral leishmaniasis (VL), the most severe form of leishmaniasis, remains a major public health challenge, with East Africa accounting for around 70% of the global disease burden.

How do we know when a visceral #leishmaniasis treatment is truly working? New research EVI-led #PREV_PKDL project identifies immune biomarkers that track treatment response in VL.

🔗 www.euvaccine.eu/post/new-stu...
#NTDs @plos.org